Applying Strategic Analysis to Quantify Investor Risk of Pfizer Pharmaceuticals

Brian J. Galli
Additional contact information
Brian J. Galli: Assistant Professor and Graduate Program Director, Master of Science in Engineering Management Industrial Engineering, Hofstra University, USA

International Journal of Risk and Contingency Management (IJRCM), 2017, vol. 6, issue 3, 1-13

Abstract: This study analyzes Pfizer Pharmaceuticals, one of the leading pharmaceutical companies in the global market. A strategic analysis is presented in order to understand the liquidity, asset utilization, profitability, stability and debt management, and investor ratios of Pfizer. In this study, the strategic analysis is undergone, and each of the contributing factors is further explained. Suggestions about how management can mend and/or maintain the results in each factor of the strategic analysis are offered. The study concludes by suggesting whether or not it is viable for an equity investor to add Pfizer Pharmaceuticals to his/her portfolio of investments. Its contribution to future research is in the form of suggestions for management to take in order to mitigate financial risk and increase profitability.

Date: 2017
References: Add references at CitEc
Citations:

Downloads: (external link)
http://services.igi-global.com/resolvedoi/resolve. ... 018/IJRCM.2017070101 (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:igg:jrcm00:v:6:y:2017:i:3:p:1-13

Access Statistics for this article

International Journal of Risk and Contingency Management (IJRCM) is currently edited by Narasimha Rao Vajjhala

More articles in International Journal of Risk and Contingency Management (IJRCM) from IGI Global
Bibliographic data for series maintained by Journal Editor ().